- Home
- ASND vs NLY Comparison
ASND vs NLY Comparison
Compare ASND & NLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASND
- NLY
- Stock Information
- Founded
- ASND 2006
- NLY 1996
- Country
- ASND Denmark
- NLY United States
- Employees
- ASND 1017
- NLY N/A
- Industry
- ASND Biotechnology: Pharmaceutical Preparations
- NLY Real Estate Investment Trusts
- Sector
- ASND Health Care
- NLY Real Estate
- Exchange
- ASND Nasdaq
- NLY Nasdaq
- Market Cap
- ASND 12.2B
- NLY 13.2B
- IPO Year
- ASND 2015
- NLY 1997
- Fundamental
- Price
- ASND $208.32
- NLY $21.49
- Analyst Decision
- ASND Strong Buy
- NLY Buy
- Analyst Count
- ASND 17
- NLY 9
- Target Price
- ASND $245.76
- NLY $21.63
- AVG Volume (30 Days)
- ASND 407.0K
- NLY 6.8M
- Earning Date
- ASND 11-04-2025
- NLY 10-22-2025
- Dividend Yield
- ASND N/A
- NLY 13.02%
- EPS Growth
- ASND N/A
- NLY N/A
- EPS
- ASND N/A
- NLY 2.19
- Revenue
- ASND $576,332,355.00
- NLY $1,748,174,000.00
- Revenue This Year
- ASND $104.98
- NLY $355.50
- Revenue Next Year
- ASND $79.91
- NLY $5.70
- P/E Ratio
- ASND N/A
- NLY $9.80
- Revenue Growth
- ASND 54.50
- NLY 275.23
- 52 Week Low
- ASND $118.03
- NLY $16.60
- 52 Week High
- ASND $216.45
- NLY $22.45
- Technical
- Relative Strength Index (RSI)
- ASND 57.09
- NLY 58.40
- Support Level
- ASND $195.03
- NLY $20.50
- Resistance Level
- ASND $208.39
- NLY $21.22
- Average True Range (ATR)
- ASND 8.24
- NLY 0.38
- MACD
- ASND -0.46
- NLY 0.06
- Stochastic Oscillator
- ASND 78.36
- NLY 90.91
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About NLY Annaly Capital Management Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are; the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.